Suvanand Sahu
Biographic Data
| ID | 6891860 |
|---|---|
| NAME | Suvanand Sahu |
| GIVEN NAMES | Suvanand |
| FAMILY NAME | Sahu |
| SIGNATURE | SAHU S |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 1 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 1 |
A deadly equation
The recent withdrawal of U.S. financial support threatens essential TB service delivery, including diagnostics, treatment, TB-HIV co-infection interventions and research initiatives critical to eradicating TB. This study analyses the dependency of and potential impact of funding cuts to 26 high-burden TB countries (HBCs). We modelled three recovery scenarios: (1) minimal impact (services recover within three months), (2) moderate impact (recovery…
One Million Lives Saved Per Year
This report presents a cost–benefit analysis of increased spending on tuberculosis (TB) using impacts and costs drawn from the Global Plan to End Tuberculosis, 2023–2030. The analysis indicates that the return on TB spending is substantial with a centrally estimated benefit–cost ratio (BCR) of 46, meaning every US$ 1 invested in TB yields US$ 46 in benefits. Alternative specifications using different baselines, interventions, cost profiles, and d…
Lifesaving, cost-saving
Aastha Gupta is a consultant to the Global Alliance for TB Drug Development (TB Alliance), a non-profit organization dedicated to the discovery and development of improved TB therapeutics
One Million Lives Saved Per Year
This report presents a cost–benefit analysis of increased spending on tuberculosis (TB) using impacts and costs drawn from the Global Plan to End Tuberculosis, 2023–2030. The analysis indicates that the return on TB spending is substantial with a centrally estimated benefit–cost ratio (BCR) of 46, meaning every US$ 1 invested in TB yields US$ 46 in benefits. Alternative specifications using different baselines, interventions, cost profiles, and d…
Lifesaving, cost-saving
Aastha Gupta is a consultant to the Global Alliance for TB Drug Development (TB Alliance), a non-profit organization dedicated to the discovery and development of improved TB therapeutics
One Million Lives Saved Per Year
This report presents a cost–benefit analysis of increased spending on tuberculosis (TB) using impacts and costs drawn from the Global Plan to End Tuberculosis, 2023–2030. The analysis indicates that the return on TB spending is substantial with a centrally estimated benefit–cost ratio (BCR) of 46, meaning every US$ 1 invested in TB yields US$ 46 in benefits. Alternative specifications using different baselines, interventions, cost profiles, and d…
A deadly equation
The recent withdrawal of U.S. financial support threatens essential TB service delivery, including diagnostics, treatment, TB-HIV co-infection interventions and research initiatives critical to eradicating TB. This study analyses the dependency of and potential impact of funding cuts to 26 high-burden TB countries (HBCs). We modelled three recovery scenarios: (1) minimal impact (services recover within three months), (2) moderate impact (recovery…
Tuberculosis (3 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Medicine (2 works) · Psychological intervention (2 works) · Tuberculosis Research and Epidemiology (2 works) · Actuarial science (1 work) · Benefit–cost ratio (1 work) · Cost–benefit analysis (1 work) · COVID-19 epidemiological studies (1 work) · Death toll (1 work)